3,6-DMAD dihydrochloride

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

3,6-DMAD dihydrochloride

CAS No. : 2226511-77-7

MCE 国际站：3,6-DMAD dihydrochloride

产品活性：3,6-DMAD dihydrochloride 是一种吖啶衍生物，是一种有效的 IRE1α-XBP1s 通路抑制剂。 3,6-DMAD dihydrochloride 通过 IRE1α-XBP1s 通路促进 IL-6 分泌。3,6-DMAD dihydrochloride 可抑制 IRE1α 寡聚化和核糖核酸内切酶 (RNase) 活性。3,6-DMAD dihydrochloride 可用于癌症的研究。

研究领域：Cell Cycle/DNA Damage

作用靶点：IRE1

In Vitro: 3,6-DMAD dihydrochloride (0-6 μM; 24 h; RPMI 8226 and MM1.R human MM cells) has cytotoxicity against MM cell lines.
3,6-DMAD dihydrochloride (0-30 μM; 14 h; HT1080 cells treated with Tg (0.3 μM)) inhibits XBP1 splicing (XBP1s) in a dose dependent manner.
3,6-DMAD dihydrochloride (0.1-500 μM; 14 h; HT1080 cells treated with Tg (0.3 μM)) inhibits IRE1α endonuclease activity.
3,6-DMAD dihydrochloride (1-60 μM; 2 h; HEK293 cells) inhibits IRE1α oligomerization and IRE1α-GFP foci formation.

In Vivo: 3,6-DMAD dihydrochloride (10 mg/kg; i.p.; three times every 12 hours, for 84 hours; NOD Scid mice with RPMI 8226 xenograft) has inhibition of XBP1 splicing in vivo.
3,6-DMAD dihydrochloride (10 mg/kg; 24 h; i.p.; every 48 hours, for 12 days; NOD Scid mice with RPMI 8226 xenograft) suppresses multiple myeloma xenograft growth in vivo.

相关产品：Sunitinib  |  4μ8C  |  STF-083010  |  IXA4  |  MKC8866  |  KIRA6  |  Toyocamycin  |  Kira8  |  GSK2850163  |  APY29  |  MKC3946  |  B I09  |  IXA6  |  IRE1α kinase-IN-1  |  MKC9989  |  IRE1α kinase-IN-2  |  3,6-DMAD hydrochloride  |  Z4P  |  6-Bromo-2-hydroxy-3-methoxybenzaldehyde  |  KIRA-7  |  IRE1α kinase-IN-3  |  IRE1α kinase-IN-4  |  IRE1α kinase-IN-5  |  IRE1α kinase-IN-6  |  IRE1α kinase-IN-7  |  IRE1α kinase-IN-8  |  IRE1α kinase-IN-9

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds